It is a link for moving within the page.

  1. HOME
  2. About Otsuka
  3. News Releases
  4. 2016
  5. Otsuka and Medimetriks Sign Licensing Agreement for Development and Commercialization of OPA-15406 in the U.S. for Atopic Dermatitis

February 9, 2016

Otsuka Pharmaceutical Co., Ltd.

Pharmaceuticals

Otsuka and Medimetriks Sign Licensing Agreement for Development and Commercialization of OPA-15406 in the U.S. for Atopic Dermatitis

Otsuka Pharmaceutical Co., Ltd. and Medimetriks Pharmaceuticals, Inc. (based in Fairfield, New Jersey, U.S.) announced that they entered into a licensing agreement on February 8 (U.S. date).
The agreement provides Medimetriks, a company specializing in the dermatology market, with development, marketing and manufacturing rights to OPA-15406 in the United State. Otsuka receives a USD 22 million lump sum payment (approximately Yen 2.5 billion) and additional milestones through regulatory approval.
Otsuka discovered the molecule OPA-15406, a new therapeutic agent in development for atopic dermatitis. OPA-15046 has inhibitory effects on phosphodiesterase IV (PDE-4).


Information in this news release was current as of the original release date.

Latest Pharmaceutical Business related News Releases

Most Recent Releases